The inclusion criteria were: (1) patients included in eachtrails were cytologically or pathologically confirmed cases ofhepatocellular cancer; (2) patients were given KLT injectioncombined with hepatic arterial intervention or hepatic arterialintervention alone;(3) short-term efficacy such as completeresponse, partial response or objective response rate shouldbe provided in results of each study;(4) the study design shouldbe prospective randomized controlled trails (RCTs).